Redirecting to https://www.morningstar.com/news/pr-newswire/20260531cn71981/d3-bio-presents-first-line-data-for-elisrasib-d3s-001-at-asco-2026-next-generation-kras-g12c-inhibitor-shows-landmark-efficacy-in-untreated-nsclc